Logo image of CRIS

CURIS INC (CRIS) Stock Price, Quote, News and Overview

NASDAQ:CRIS - Nasdaq - US2312693094 - Common Stock - Currency: USD

1.81  +0.06 (+3.43%)

After market: 1.73 -0.08 (-4.42%)

CRIS Quote, Performance and Key Statistics

CURIS INC

NASDAQ:CRIS (7/3/2025, 7:14:03 PM)

After market: 1.73 -0.08 (-4.42%)

1.81

+0.06 (+3.43%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High8.29
52 Week Low1.02
Market Cap18.93M
Shares10.46M
Float9.56M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-30 2025-07-30/bmo
IPO08-01 2000-08-01


CRIS short term performance overview.The bars show the price performance of CRIS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

CRIS long term performance overview.The bars show the price performance of CRIS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CRIS is 1.81 USD. In the past month the price decreased by -23.31%. In the past year, price decreased by -71.63%.

CURIS INC / CRIS Daily stock chart

CRIS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.43 334.34B
AMGN AMGEN INC 14.37 160.37B
GILD GILEAD SCIENCES INC 14.44 139.01B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.03B
REGN REGENERON PHARMACEUTICALS 12.35 59.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 43.28B
ARGX ARGENX SE - ADR 94.52 33.18B
ONC BEONE MEDICINES LTD-ADR 6.26 26.57B
BNTX BIONTECH SE-ADR N/A 26.44B
NTRA NATERA INC N/A 22.09B
BIIB BIOGEN INC 8.4 19.47B
SMMT SUMMIT THERAPEUTICS INC N/A 18.23B

About CRIS

Company Profile

CRIS logo image Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Company Info

CURIS INC

128 Spring Street, Building C, Suite 500

Lexington MASSACHUSETTS 02421 US

CEO: James Dentzer

Employees: 34

CRIS Company Website

CRIS Investor Relations

Phone: 16175036500

CURIS INC / CRIS FAQ

What is the stock price of CURIS INC today?

The current stock price of CRIS is 1.81 USD. The price increased by 3.43% in the last trading session.


What is the ticker symbol for CURIS INC stock?

The exchange symbol of CURIS INC is CRIS and it is listed on the Nasdaq exchange.


On which exchange is CRIS stock listed?

CRIS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CURIS INC stock?

11 analysts have analysed CRIS and the average price target is 16.66 USD. This implies a price increase of 820.44% is expected in the next year compared to the current price of 1.81. Check the CURIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CURIS INC worth?

CURIS INC (CRIS) has a market capitalization of 18.93M USD. This makes CRIS a Nano Cap stock.


How many employees does CURIS INC have?

CURIS INC (CRIS) currently has 34 employees.


What are the support and resistance levels for CURIS INC (CRIS) stock?

CURIS INC (CRIS) has a support level at 1.74 and a resistance level at 2.16. Check the full technical report for a detailed analysis of CRIS support and resistance levels.


Is CURIS INC (CRIS) expected to grow?

The Revenue of CURIS INC (CRIS) is expected to grow by 9.3% in the next year. Check the estimates tab for more information on the CRIS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CURIS INC (CRIS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CURIS INC (CRIS) stock pay dividends?

CRIS does not pay a dividend.


When does CURIS INC (CRIS) report earnings?

CURIS INC (CRIS) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of CURIS INC (CRIS)?

CURIS INC (CRIS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.23).


What is the Short Interest ratio of CURIS INC (CRIS) stock?

The outstanding short interest for CURIS INC (CRIS) is 1.16% of its float. Check the ownership tab for more information on the CRIS short interest.


CRIS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to CRIS. When comparing the yearly performance of all stocks, CRIS is a bad performer in the overall market: 87.19% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CRIS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CRIS. Both the profitability and financial health of CRIS have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CRIS Financial Highlights

Over the last trailing twelve months CRIS reported a non-GAAP Earnings per Share(EPS) of -6.23. The EPS increased by 27.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -107.13%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%39.02%
Sales Q2Q%14.09%
EPS 1Y (TTM)27.64%
Revenue 1Y (TTM)14.17%

CRIS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to CRIS. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 55.31% and a revenue growth 9.3% for CRIS


Ownership
Inst Owners44.65%
Ins Owners8.63%
Short Float %1.16%
Short Ratio1.27
Analysts
Analysts81.82
Price Target16.66 (820.44%)
EPS Next Y55.31%
Revenue Next Year9.3%